In the BioHarmony Drug Report Database
Guselkumab
Tremfya (guselkumab) is an antibody pharmaceutical. Guselkumab was first approved as Tremfya on 2017-07-13. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis.
Trade Name
|
Tremfya |
|---|---|
Common Name
|
guselkumab |
ChEMBL ID
|
CHEMBL2364648 |
Indication
|
psoriasis |
Drug Class
|
Monoclonal antibodies: fully human, interleukins as target |
Image (chem structure or protein)
